This review, largely written for a medical audience, addresses the effects and adverse effects found after MDMA and related drugs, GHB and related drugs and ephedrine. Strong points are in description of management for adverse effects (such as hyperthermia). However, the author paid less attention to the importance of cooling hyperthermic patients than might be warranted (see Henry & Rella, 2001), and little attempt is made to separate extremely rare adverse events (hypernatremiak for instance) from relatively more common ones. Weak points relate to the author's grasp of MDMA and knowledge concerning drug-coadministration in ecstasy users. For example, there is no evidence that ecstasy users intentionally combine dextromethorphan (sometimes sold as "ecstasy") with MDMA. The subjective effects the author ascribes to a "low" dose (50 mg, as stated in the review) of MDMA are more appropriately ascribed to a "medium" or "high" dose (100-150 mg). Not all statements are supported with references. The review might assist health professionals in treating some adverse events, but it does not provide consistently accurate information on the demographics of ecstasy use or the effects and pharmacology of MDMA.